PDF(Pubmed)
Abstract：
UNASSIGNED: This retrospective study evaluates the efficacy of camrelizumab combined with anlotinib versus chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) undergoing second-line treatment.
UNASSIGNED: Data were sourced from medical records at a Chinese medical facility, involving 34 patients diagnosed with ES-SCLC after failing first-line treatment. Patients were divided into two groups: one received camrelizumab (200 mg every 3 weeks) with anlotinib (12 mg daily for 14 days followed by a 7-day rest), while the other group received physician-chosen chemotherapy administered every 3 weeks. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and disease control rate (DCR).
UNASSIGNED: The combination therapy group showed a significant improvement in PFS compared to the chemotherapy group (median PFS: 7 months vs. 3 months; hazard ratio (HR): 0.34; 95% confidence interval (CI): 0.15-0.77; p<0.001). However, there was no statistically significant difference in OS between the groups (16.3 months vs. 17.3 months; p=0.82). The ORR was 52.9% in the combination therapy group versus 23.5% in the chemotherapy group (p=0.08), and the DCR was 82.4% compared to 58.8% (p=0.26). Grade 3 or higher adverse events were observed in 17.6% of the combination therapy group and 29.4% of the chemotherapy group.
UNASSIGNED: The findings suggest that the combination of camrelizumab and anlotinib offers a superior anti-tumor response with a manageable safety profile in a second-line setting for ES-SCLC patients. This combination regimen may be a viable option for second-line ES-SCLC treatment.
UNASSIGNED: Data were sourced from medical records at a Chinese medical facility, involving 34 patients diagnosed with ES-SCLC after failing first-line treatment. Patients were divided into two groups: one received camrelizumab (200 mg every 3 weeks) with anlotinib (12 mg daily for 14 days followed by a 7-day rest), while the other group received physician-chosen chemotherapy administered every 3 weeks. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and disease control rate (DCR).
UNASSIGNED: The combination therapy group showed a significant improvement in PFS compared to the chemotherapy group (median PFS: 7 months vs. 3 months; hazard ratio (HR): 0.34; 95% confidence interval (CI): 0.15-0.77; p<0.001). However, there was no statistically significant difference in OS between the groups (16.3 months vs. 17.3 months; p=0.82). The ORR was 52.9% in the combination therapy group versus 23.5% in the chemotherapy group (p=0.08), and the DCR was 82.4% compared to 58.8% (p=0.26). Grade 3 or higher adverse events were observed in 17.6% of the combination therapy group and 29.4% of the chemotherapy group.
UNASSIGNED: The findings suggest that the combination of camrelizumab and anlotinib offers a superior anti-tumor response with a manageable safety profile in a second-line setting for ES-SCLC patients. This combination regimen may be a viable option for second-line ES-SCLC treatment.
摘要：
■这项回顾性研究评估了康瑞珠单抗联合安洛替尼与化疗对接受二线治疗的广泛期小细胞肺癌（ES-SCLC）患者的疗效。
■数据来自中国医疗机构的医疗记录，涉及34例一线治疗失败后诊断为ES-SCLC的患者。患者分为两组：一组接受卡利珠单抗（每3周200mg）和安洛替尼（每天12mg，共14天，然后休息7天）。而另一组接受医生选择的化疗每3周一次.主要终点是无进展生存期（PFS），次要终点包括总生存期（OS），客观反应率（ORR），疾病控制率（DCR）。
■与化疗组相比，联合治疗组的PFS显着改善（中位PFS：7个月与3个月；风险比（HR）：0.34；95％置信区间（CI）：0.15-0.77；p<0.001）。然而,两组之间的OS无统计学差异(16.3个月vs.17.3个月；p=0.82）。联合治疗组的ORR为52.9％，而化疗组为23.5％（p=0.08），DCR为82.4%，为58.8%(p=0.26)。在联合治疗组的17.6%和化疗组的29.4%中观察到3级或更高的不良事件。
■研究结果表明，卡姆瑞珠单抗和安洛替尼的组合在二线环境中对ES-SCLC患者提供了优异的抗肿瘤反应和可控的安全性。这种组合方案可能是二线ES-SCLC治疗的可行选择。
■数据来自中国医疗机构的医疗记录，涉及34例一线治疗失败后诊断为ES-SCLC的患者。患者分为两组：一组接受卡利珠单抗（每3周200mg）和安洛替尼（每天12mg，共14天，然后休息7天）。而另一组接受医生选择的化疗每3周一次.主要终点是无进展生存期（PFS），次要终点包括总生存期（OS），客观反应率（ORR），疾病控制率（DCR）。
■与化疗组相比，联合治疗组的PFS显着改善（中位PFS：7个月与3个月；风险比（HR）：0.34；95％置信区间（CI）：0.15-0.77；p<0.001）。然而,两组之间的OS无统计学差异(16.3个月vs.17.3个月；p=0.82）。联合治疗组的ORR为52.9％，而化疗组为23.5％（p=0.08），DCR为82.4%，为58.8%(p=0.26)。在联合治疗组的17.6%和化疗组的29.4%中观察到3级或更高的不良事件。
■研究结果表明，卡姆瑞珠单抗和安洛替尼的组合在二线环境中对ES-SCLC患者提供了优异的抗肿瘤反应和可控的安全性。这种组合方案可能是二线ES-SCLC治疗的可行选择。
